Genentech, a member of the Roche Group (ROG.SW, RO.SW) announced positive results from the Phase II M13-982 study of venetoclax, an investigational medicine being developed in partnership with AbbVie. The study met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells in a pre-defined proportion of people with previously treated chronic lymphocytic leukemia harboring the 17p deletion.
Venetoclax was recently granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of previously treated chronic lymphocytic leukemia with the 17p deletion.
For comments and feedback: editorial@rttnews.com